ZegeneX Therapeutics Logo
Home 1. Company (Purpose, Team, Partners) 2. About Us (Vision, DFU, Market) 3. Our Science (Mechanism) 4. Product Pipeline (Indications) Videos & Media Gallery 5. News (Press & Publications)
6. Contact Us
Preclinical-Stage Biotech · IND-Enabling

Healing Reimagined.
A Revolution in Wound Care.

A first-in-class, shelf-stable small-molecule therapeutic engineered to accelerate healing in chronic and complex wounds — biologic-level efficacy, small-molecule simplicity, and ambient-temperature deployment, anywhere on Earth.

Discover the Science Explore Zegen-X5
Lead Therapeutic Candidate
Zegen-X5 · 30g
Zegenex Wound Healing Cream - Advanced & Fast-Acting Formula
2X Faster
At Day 10 (Closure)
9+ Months
Proven Ambient (25°C)
IND-Ready
Preclinical Complete
US Full Patent - University of Pittsburgh
US Full Patent

Zegenex has secured IP

The composition of Zegenex wound healing approach has secured the US Full Patent (University of Pittsburgh)

Zegenex wound healing technology licensing completed
Zegenex has secured Trademark from USPTO
Real Impact. A Healthier Tomorrow.

Advancing Wound Care Worldwide

Transforming outcomes for millions with a novel, science-backed healing solution.

$18B+
Advanced Wound-Care Market

Addressing a high-growth $14.5B (2025) market reaching $25B+ by 2032 within a $22–27B overall sector.

18.6M
DFU Patients Worldwide

18.6M global patients; 1.6M in the US facing non-healing ulcers and severe amputation risk.

2X
Wound Closure at Day 10

2X acceleration in wound closure vs. vehicle control in preclinical excisional models at Day 10.

First-in-Class
Novel Mechanism of Action

Upstream master activator avoiding receptor desensitization.

Better Healing. Brighter Lives.
3D DNA Double Helix Molecular Structure
VISION & PURPOSE

Healing,
Reimagined.

A New Dawn in Wound Care

We are advancing a new era in wound care—where the body's natural healing potential is unlocked, complications are prevented, and more lives are restored.

01

Our Vision

A world where no acute injury is left to become a permanent wound, get infected and end up in amputation.

02

Why We Exist

An acute injury; a cut, a burn, a small wound should heal and be forgotten. But for millions of patients, that same injury stalls, lingers, and becomes a chronic wound that reshapes their life: diabetic foot ulcers, burns, lacerations that simply won't close. We exist to change that trajectory, helping patients heal fully.

03

Our Mission

To empower patients to heal persistent, chronic, non-healing wounds and prevent amputations by restoring the body's innate capacity to repair before infection sets in, turning healing from a years-long condition to manage into an achievable, positive outcome.

Backed by World-Class Science & Strategic Capital
Richard King Mellon Foundation IND-Enabling Preclinical Complete US Composition-of-Matter IP Academic Medical Research Collaboration
The Unmet Need

Wound care hasn’t truly
changed in decades.
And patients are paying the price.

Over 8.2 million Americans live with chronic, non-healing wounds. The current standard of care fails one in four — leading to amputation, systemic infection, and avoidable mortality.

8.2M+
Americans with chronic wounds
1 in 4
Current treatments fail
High
Risk of amputation, infection & mortality

Cold-Chain Dependency

Existing growth-factor biologics like becaplermin require strict refrigeration and have hours-long stable life once reconstituted — making them virtually impossible to deploy in rural, military, or low-resource emergency settings.

→ Learn more

Limited Efficacy

External biologics suffer from rapid receptor downregulation and feedback inhibition. 94% of US DFU patients never receive advanced therapy, relying on basic dressings that fail to rescue stalled biological pathways.

→ Learn more

Crushing Cost Barrier

Cellular and tissue-based products cost $5,000–$15,000 per course and require specialized clinical prep. This extreme price tag makes them inaccessible for the vast majority of global healthcare systems.

→ Learn more
A Brighter Tomorrow For Wound Care
Crystalline DNA Helix Background
THE ZEGENEX SOLUTION

Biologic-level efficacy.
Small-molecule simplicity.

Our proprietary small molecule activates upstream regulators of the body's natural healing cascade — driving rapid keratinocyte proliferation, capillary angiogenesis, and organized re-epithelialization through a mechanism never previously exploited by an approved therapeutic.

Novel MOA

Amplifies endogenous tissue-repair cascades rather than dumping fragile external growth factors.

Thermostable & Field-Ready

>95% potency at 25°C for 9+ months (proven stability); withstands extreme heat spikes without degradation.

Scalable Synthesis

Manufactured at a fraction of recombinant biologic bioreactor costs.

Multi-Format Adaptability

Topical application, protective matrix barrier, touchless spray, or targeted delivery.

Read the Full Scientific Mechanism →
PRECLINICAL PERFORMANCE DATA

Validated Across Standard & Diabetic In Vivo Models

2X
Wound closure rate
at Day 10 vs. control
~90%
Closure in diabetic models
at Day 10
9+ Mo
Proven shelf stability
(25°C ambient)
0
Adverse events
in tox cohorts
Model: Murine db/db excisional Statistical significance: p < 0.001
REAL SCIENCE. REAL HEALING. A BRIGHTER TOMORROW.
Why ZegeneX

Six reasons this is the future of wound healing

Built on rigorous cellular biology, validated across animal models, and engineered for scalable real-world application.

01

First-in-Class MOA

A novel molecular target with no approved therapeutic in the space — providing a pristine IP runway and category-defining commercial potential.

02

De-risked Science

Complete preclinical package: in-vitro efficacy across 3 human cell lines, murine diabetic models, non-GLP pig tox, and ICH-compliant stability.

03

Ambient Stability

Zero cold-chain dependence. Unlocks global distribution across retail pharmacies, rural outpatient clinics, defense triage, and emerging markets.

04

Exceptional Unit Economics

Chemical small-molecule synthesis yields 85%+ gross margins at scale, enabling disruptive pricing and high profitability.

05

Broad Indications

Lead program in DFU, followed rapidly by venous leg ulcers, deep burn trauma, post-surgical dehiscence, and military field triage.

06

Comprehensive IP Estate

Granted composition-of-matter patents in the US and key international jurisdictions with patent protection extending into the 2040s.

CLINICAL ROADMAP

Clear Path to Commercialization

Structured clinical development designed for capital efficiency and rapid regulatory milestones.

Complete 2024–2025

Preclinical Package

Preclinical efficacy, cellular target validation, stability assessment, and non-GLP safety studies.

In Progress H1 2026

GLP Tox & Pre-IND

Porcine GLP toxicology, CMC scale-up, FDA pre-IND briefing submission.

Upcoming 2026–2027

Phase Ib (60 DFU)

First-in-human open-label safety, tolerability & preliminary wound closure rate in DFU patients.

Future 2027–2028

Phase IIb & Partnering

180-patient randomized controlled trial vs standard of care; global commercial partnership.

Science in Motion · Video Archive

Watch the Breakthrough
Science of Zegen-X5

From foundational genetic discoveries at the University of Pittsburgh to room-temperature stable therapeutics and point-of-care clinical delivery.

Explore Video Gallery
Featured Presentation

ZegeneX Therapeutics: Executive Overview & Clinical Vision

Translational origins from the University of Pittsburgh and IND-enabling clinical development for chronic diabetic ulcers.

ZegeneX Therapeutics: Executive Overview & Clinical Vision
EXECUTIVE PRESENTATION
1:23

ZegeneX Therapeutics: Executive Overview & Clinical Vision

A comprehensive overview of ZegeneX Therapeutics' revolutionary small-molecule regenerative wound healing platform, its translational origins at the University of Pittsburgh, and upcoming IND-enabling clinical trajectory for diabetic foot ulcers.

Details →
Complete 5-Phase Wound Healing Mechanism of Action
MOA 3D ANIMATION
1:48

Complete 5-Phase Wound Healing Mechanism of Action

Comprehensive scientific animation detailing the 5 biological phases of wound repair—from initial platelet plug formation and immune debridement to cellular proliferation, myofibroblast contraction, and epidermal remodeling.

Details →
Translational Laboratory Footage: Zebrafish Screening & Kinase Assay
PITT LAB RESEARCH
2:03

Translational Laboratory Footage: Zebrafish Screening & Kinase Assay

Exclusive footage inside the University of Pittsburgh developmental biology laboratories showcasing high-throughput transgenic zebrafish genetic assays, fluorescent biosensors, cellular re-epithelialization imaging, and translational tissue regeneration research.

Details →

Dedicated Video Page →
News & Insights

Latest from Our Research Community

Discover breakthroughs, stories and perspectives shaping the future of wound care and regenerative medicine.

View All Articles

Stay Updated

Get the latest research news, clinical insights and company updates delivered to your inbox.

Subscribe Now
Partner With Us

Help write the next chapter of wound care.

We work with strategic biopharma partners, foundation grants, and visionary investors who share our conviction that healing should be universal — not constrained by infrastructure, refrigeration, or geography.

Explore Partnerships Request Confidential Briefing